6 completed, 5 recruiting, 3 active not recruiting, 3 unknown. 18 Phase 2, 6 Phase 1, 2 Phase 3.
Follow monalizumab: new trials by email Literature Review of monalizumab trials Research Report on monalizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 Durvalumab, Monalizumab, Oleclumab - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Montefiore Medical Center | 52 | 2026-09-01 | 2026-06-09 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer Durvalumab, Monalizumab - Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | John Sfakianos | 60 | 2025-02-24 | 2026-10-05 |
| Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer Monalizumab/MEDI5257 - MSI, dMMR Colorectal Cancer | Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2023-12-01 | 2026-04-06 | |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer Durvalumab, Monalizumab, Carboplatin or Cisplatin - Small Cell Lung Cancer, SCLC | Phase 2 | Recruiting | Hirva Mamdani | 84 | 2023-09-26 | 2026-04-29 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 630 | 2022-04-14 | 2026-10-21 |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1051 | 2022-02-07 | 2026-06-18 |
| Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation Monalizumab (anti-NKG2A monoclonal antibody) - Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Istituto Clinico Humanitas | 42 | 2021-12-03 | 2025-03-24 |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial Monalizumab, Trastuzumab - Breast Cancer | Phase 2 | Completed | The Netherlands Cancer Institute | 12 | 2021-03-23 | 2024-10-22 |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer Monalizumab, Cetuximab, Placebo - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Active not recruiting | AstraZeneca | 370 | 2020-10-02 | 2026-09-09 |
| Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC Standard of Care - mFOLFOX6, E1 - mFOLFOX and durvalumab, E2 - mFOLFOX6, durvalumab and oleclumab - Microsatellite-stable Colorectal Cancer | Phase 2 | Withdrawn | MedImmune LLC | 2020-10-01 | 2020-09-21 | |
| Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection Autophagy inhibitor (GNS651), Standard of care, Avdoralimab - SARS-CoV-2 (COVID-19) Infection, Advanced or Metastatic Hematological or Solid Tumor | Phase 2 | Completed | Centre Leon Berard | 19 | 2020-04-15 | 2022-09-30 |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2019-10-28 | 2025-09-23 |
| Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance Durvalumab (MEDI4736), Monalizumab (IPH2201), Oleclumab (MEDI9447) - Non-small Cell Lung Cancer | Phase 2 | Unknown | Assistance Publique Hopitaux De Marseille | 114 | 2019-10-08 | 2024-05-03 |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage | Phase 2 | Completed | MedImmune LLC | 84 | 2019-03-08 | 2022-02-24 |
| Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab - Stage III Non-small Cell Lung Cancer, Unresectable | Phase 2 | Completed | MedImmune LLC | 189 | 2018-12-19 | 2024-10-08 |
| Biomarker-based Study in R/M SCCHN Afatinib, Palbociclib, standard of care - Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 2017-11-16 | 2023-11-03 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA Monalizumab, Oxaliplatin, 5-Fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Jules Bordet Institute | 2017-07-20 | 2017-12-19 | |
| Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation Monalizumab - Hematologic Malignancies | Phase 1 | Unknown | Institut Paoli-Calmettes | 18 | 2016-11-28 | 2018-09-19 |
| A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors Monalizumab, Durvalumab, Cetuximab - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | MedImmune LLC | 383 | 2016-02-22 | 2026-06-15 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Neoplasms (4) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma Of Esophagus (1) · Anemia, Refractory, with Excess of Blasts (1) · Breast Neoplasms (1) · COVID-19 (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Hematologic Neoplasms (1)
MedImmune LLC (4) · AstraZeneca (3) · Innate Pharma (2) · Assistance Publique - Hôpitaux de Paris (1) · Assistance Publique Hopitaux De Marseille (1) · Centre Leon Berard (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hirva Mamdani (1) · Institut Paoli-Calmettes (1) · Istituto Clinico Humanitas (1) · John Sfakianos (1) · Jules Bordet Institute (1) · Montefiore Medical Center (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1)
United States (13) · France (12) · Italy (8) · Spain (7) · Canada (6) · Belgium (5) · Portugal (5) · South Korea (4) · Taiwan (4) · United Kingdom (4) · Australia (3) · Poland (3) · Brazil (2) · Germany (2) · Hungary (2)
Amelie Deleporte, Physician (1) · Anne C Chiang (1) · Dario Ruscica, MD (1) · Fabrice Barlesi, MD (1) · Hirva Mamdani, MD (1) · John Sfakianos, MD (1) · Kerry A Rogers, MD (1) · Marleen Kok, MD (1) · Nitin R Ohri, MD (1) · Roger B Cohen, MD (1) · Steven H Lin (1)
PMID 36852723, PMID 30307465, PMID 35452273, PMID 37707791, PMID 38309722, PMID 39023287, PMID 40450142, PMID 40663352, PMID 41151963
2016 (2), 2018 (2), 2023 (2), 2017 (1), 2019 (1), U10CA180868 (1), U10CA180888 (1)